ArticleCancer reports (Hoboken, N.J.)2026
Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) are associated with a spectrum of cardiovascular toxicities, including hypertension, atrial fibrillation, impaired cardiac function, heart failure, and arterio-occlusive events. Among these, nilotinib has been particularly linked to peripheral arterial disease and thromboembolic complications. CASE: We report the case of a 53-year-old male patient who initially presented with fatigue, malaise, and mild left upper quadrant abdominal pain. Bone marrow aspiration confirmed CML with the presence of the BCR::ABL1 fusion gene. The patient was started on nilotinib therapy. After 8 months of treatment, he developed unilateral blurred vision and sixth nerve palsy, which were attributed to a retinal arterial occlusion. No prior cardiovascular risk factors were documented. Nilotinib therapy was discontinued, and the patient was switched to dasatinib, leading to gradual improvement of visual symptoms.
conclusionThis case underlines the importance of considering rare but severe arterio-occlusive complications, such as retinal artery thrombosis, among the cardiovascular toxicities of nilotinib. Careful cardiovascular monitoring and early recognition of such events are crucial to optimize patient safety and treatment outcomes in CML management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.